Literature DB >> 15804392

Stability of DSM-IV criterion symptoms for major depressive disorder.

Kelly L Minor1, Jennifer E Champion, Ian H Gotlib.   

Abstract

Given the chronic and recurrent nature of major depressive disorder (MDD), it is important to understand whether specific symptoms are stable over time or vary over the course of the disorder. This is the first longitudinal investigation examining the stability of the nine criterion symptoms of depression, as specified in the DSM-IV, among diagnosed depressed adults who were not recovered at follow-up. In this study, participants were assessed twice, ten months apart, with the structured clinical interview for DSM-IV, and stability of the nine criterion symptoms of MDD was examined. Findings indicate strong stability in individuals' symptom profiles. Among individuals who were clinically depressed at both assessments, there were no statistically significant fluctuations in specific symptoms endorsed. Changes in symptom endorsement among individuals who no longer met diagnostic criteria for MDD at Time 2 were attributable to reduced severity (i.e., number of symptoms) rather than to inconsistency of symptom endorsement. These results indicate that depressed individuals experience essentially the same pattern of specific symptoms over the course of a year. Variation in clinical course is likely to be attributable more to fluctuations in overall severity than to changes in specific symptoms of depression.

Entities:  

Mesh:

Year:  2004        PMID: 15804392     DOI: 10.1016/j.jpsychires.2004.11.001

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  8 in total

1.  The Diagnostic Stability of DSM-IV Diagnoses: An Examination of Major Depressive Disorder, Bipolar I Disorder, and Schizophrenia in Korean Patients.

Authors:  Won Kim; Young Sup Woo; Jeong-Ho Chae; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

2.  Evaluation of the Effects of Severe Depression on Global Cognitive Function and Memory.

Authors:  Shawn M McClintock; Munro Cullum; Mustafa M Husain; A John Rush; Rebecca G Knapp; Martina Mueller; Georgios Petrides; Shirlene Sampson; Charles H Kellner
Journal:  CNS Spectr       Date:  2010-05       Impact factor: 3.790

3.  Intimate partner violence/abuse and depressive symptoms among female health care workers: longitudinal findings.

Authors:  Lareina N La Flair; Catherine P Bradshaw; Jacquelyn C Campbell
Journal:  Womens Health Issues       Date:  2011-08-25

4.  Intimate partner violence and subsequent depression and anxiety disorders.

Authors:  Zohre Ahmadabadi; Jackob M Najman; Gail M Williams; Alexandra M Clavarino; Peter d'Abbs; Nam Tran
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-01-07       Impact factor: 4.328

5.  Trajectories of individual depressive symptoms in adolescents: gender and family relationships as predictors.

Authors:  Chrystyna D Kouros; Judy Garber
Journal:  Dev Psychol       Date:  2014-10-20

6.  Augmenting neurocognitive remediation therapy to Preventive Cognitive Therapy for partially remitted depressed patients: protocol of a pragmatic multicentre randomised controlled trial.

Authors:  Claudi Bockting; Amanda M Legemaat; Johanne G J van der Stappen; Gert J Geurtsen; Maria Semkovska; Huibert Burger; Isidoor O Bergfeld; Nicoline Lous; Damiaan A J P Denys; Marlies Brouwer
Journal:  BMJ Open       Date:  2022-06-23       Impact factor: 3.006

7.  Different associations of white matter lesions with depression and cognition.

Authors:  Jun-Young Lee; Philip Insel; R Scott Mackin; Norbert Schuff; Helena Chui; Charles DeCarli; Kee Hyung Park; Susanne G Mueller; Michael W Weiner
Journal:  BMC Neurol       Date:  2012-08-25       Impact factor: 2.474

8.  Severity, course trajectory, and within-person variability of individual symptoms in patients with major depressive disorder.

Authors:  W A van Eeden; A M van Hemert; I V E Carlier; B W Penninx; E J Giltay
Journal:  Acta Psychiatr Scand       Date:  2018-12-09       Impact factor: 6.392

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.